CAR19 Tregs treat murine chronic graft-versus-host disease through immune suppression without measurable B cell cytolysis
The findings suggest that CAR19 Tregs represent a promising and safe cGVHD/BOS therapeutic strategy, offering immunosuppressive benefits and improved disease outcomes that may be more limited with CD8+ CAR19 T cell treatment.